Tag: Mindset Pharma - Psychedelic Alpha

Read more about the article Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics

Post published:March 28, 2023
Post category:Press Release

Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

Post published:March 14, 2023
Post category:Press Release

Read more about the article Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership

Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership

Post published:March 6, 2023
Post category:Press Release

Read more about the article Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Post published:February 2, 2023
Post category:Press Release

Mindset Pharma to Participate in Upcoming Conferences in December 2022

Post published:December 6, 2022
Post category:Press Release

Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

Post published:October 28, 2022
Post category:Press Release

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Post published:October 6, 2022
Post category:Press Release

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

Post published:September 28, 2022
Post category:Press Release

Read more about the article Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Post published:September 14, 2022
Post category:Press Release

Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

Post published:September 7, 2022
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics

Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma to Participate in Upcoming Conferences in December 2022

Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.